top of page


Work package 5: Phase II clinical trial in Burkina Faso

Led by Groupe de Recherche Action en Santé, Burkina Faso

The main objectives of this work package are:

  • To continue the clinical development of ShigaPlexIM in a descending age study of safety and immunogenicity in a phase II trial

  • To determine the safety and immunogenicity of two formulations of InvaplexAR-Detox in participants 10-17 years, 24-59 months and 6-11 months of age, given as three doses four weeks apart at D1, D22 and D43


LOGO GRAS 150 dpi-rvb190925.jpg
bottom of page